Zimbabwe Establishes An Intellectual Property Tribunal, As A Special Division Of High Court 13/03/2018 by Hillary Muheebwa for Intellectual Property Watch 2 Comments KAMPALA, Uganda — In what is seen as a significant achievement in the making of history of intellectual property law, the Government of Zimbabwe has instituted and operationalised an Intellectual Property Tribunal, with the mandate to speedily preside over all IP matters, disputes, infringements, passing off and other related issues. The Tribunal recently heard its first case. [A reminder to readers: All IP-Watch stories are totally free for least-developed countries and almost all developing countries. Just sign up for a password under Subscribe.]
New IP-Sharing Framework To Accelerate R&D 12/03/2018 by Intellectual Property Watch Leave a Comment Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef.
What We Know – And What We Don’t – About Counterfeit Goods And Small Parcels 08/03/2018 by Intellectual Property Watch 1 Comment Kasie Brill writes: Cross-border e-commerce is growing exponentially. Consumers can purchase products from all over the world and have them delivered straight to their doors with just the click of a button. In fact, the U.S. Postal Service’s (USPS) international small parcel business increased 232% from 2013 to 2017, when it received nearly half a billion packages. Out of those half a billion packages, USPS only had critical safety information on 36% of them. In other words, millions of packages reached American consumers with little or no security screening at all. Though most of these packages contained exactly what the customer ordered, counterfeiters have discovered that small parcels are an easy means to distribute fake and often dangerous goods.
Fair Use/Fair Dealing Week 2018 Highlights Balance In The Copyright System 08/03/2018 by Intellectual Property Watch 1 Comment The fifth annual Fair Use/Fair Dealing Week took place February 26–March 2, 2018, growing to 153 participating organizations—as well as numerous individuals—celebrating the important and flexible doctrines of fair use and fair dealing worldwide. This year’s event was organized by the Association of Research Libraries (ARL) and participants included universities, libraries, library associations, and many other organizations, such as Authors Alliance, the Center for Democracy & Technology, the Electronic Frontier Foundation, the R Street Institute, and Re:Create. Sixty ARL member institutions contributed a wide range of resources this year. Fair Use/Fair Dealing Week was observed around the globe by participants in such countries as Australia, Canada, Colombia, Greece, and the United States.
Early Certainty Initiative Of The European Patent Office – Flexibility For Biotech Needed 06/03/2018 by Intellectual Property Watch 2 Comments In 2016, the European Patent Office (EPO) introduced a streamlined opposition procedure that should simplify opposition proceedings and deliver decisions faster, while giving parties more time to react to summons and prepare for oral proceedings. This new initiative, called early certainty, aimed to cut down the overall duration of granting new patents and to tackle the backlog in patent granting within the EPO, writes Michael Kahnert.
A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents.
Protecting And Promoting Copyright Balance In NAFTA 04/03/2018 by Intellectual Property Watch 1 Comment The ongoing NAFTA renegotiation presents a prime opportunity to move the ball on protecting and promoting general public interest copyright exceptions. All three countries have such exceptions to varying degree. And all three are under threat from an agenda to cabin their use through international law. NAFTA negotiators can and should include the best models from prior international agreements that protect and promote the ability of countries to have general exceptions, writes Professor Sean Flynn.
Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies.
Section 1201 Rulemaking – The Process Is Moving Along 28/02/2018 by Intellectual Property Watch Leave a Comment Dave Davis writes: Section 1201 is a curious little section of the US Copyright Act, added by the Digital Millennium Copyright Act (DMCA) of 1998. But the matter covered in that section is of great importance in our digital age and, due to its triennial rulemaking requirement, ‘1201’ exceptions are a topic of considerable discussion every few years. As it turns out, 2018 is one of those years.
Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices 26/02/2018 by Catherine Saez and William New, Intellectual Property Watch Leave a Comment Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it.